✦ LIBER ✦

Pharmacokinetic and Pharmacodynamic Assessments of the Dipeptidyl Peptidase-4 Inhibitor PHX1149: Double-Blind, Placebo-Controlled, Single- and Multiple-Dose Studies in Healthy Subjects

✍ Scribed by A. Marie O'Farrell; Andre van Vliet; Khalid Abou Farha; Julie M. Cherrington; David A. Campbell; Xinqiang Li; Denise Hanway; Jianke Li; Hans-Peter Guler

Book ID: 116372027
Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 898 KB
Volume: 29
Category: Article
ISSN: 0149-2918
DOI: 10.1016/j.clinthera.2007.08.005

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Pharmacokinetics, pharmacodynamics, and

Pharmacokinetics, pharmacodynamics, and tolerability of single increasing doses of the dipeptidyl peptidase-4 inhibitor alogliptin in healthy male subjects

✍ Ronald Christopher; Paul Covington; Michael Davenport; Penny Fleck; Qais A. Mekk 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 267 KB

Pharmacokinetic, pharmacodynamic, and to

Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: A randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes

✍ Paul Covington; Ronald Christopher; Michael Davenport; Penny Fleck; Qais A. Mekk 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 253 KB

Pharmacokinetics, pharmacodynamics, and

Pharmacokinetics, pharmacodynamics, and tolerability of the dipeptidyl peptidase IV inhibitor LC15-0444 in healthy Korean men: A dose—block-randomized, double-blind, placebo-controlled, ascending single-dose, phase I study

✍ Kyoung Soo Lim; Jung-Ryul Kim; Yun-Jung Choi; Kwang-Hee Shin; Kyu-Pyo Kim; Jang- 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 169 KB

Linagliptin, a dipeptidyl peptidase-4 in

Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: A phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male japanese subjects

✍ Akiko Sarashina; Shogo Sesoko; Mitsuyoshi Nakashima; Naoyuki Hayashi; Atsushi Ta 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 212 KB

Tolerability and pharmacokinetics of ava

Tolerability and pharmacokinetics of avanafil, a phosphodiesterase type 5 inhibitor: A single- and multiple-dose, double-blind, randomized, placebo-controlled, dose-escalation study in healthy Korean male volunteers

✍ Jinah Jung; Sangmin Choi; Sang Heon Cho; Jong-Lyul Ghim; Aekyung Hwang; Unjib Ki 📂 Article 📅 2010 🏛 Elsevier Science 🌐 English ⚖ 128 KB

561 Safety and pharmacokinetics of the n

561 Safety and pharmacokinetics of the now nucleoside polymerase inhibitor, HCV-796: Results of a randomized, double-blind, placebo-controlled, ascending single-dose study in healthy subjects

✍ P. Chandra; D. Raible; L. Moyer; D. Harper; J. Speth; S. Villano; R. Fruncillo 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 235 KB